Opendata, web and dolomites

TiDrugArchitectures SIGNED

Highly Competent and Safe Titanium(IV) Therapeutic Frameworks that are Cancer Targeted based on Complex 1, 2, and 3D Chemical Architectures

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TiDrugArchitectures project word cloud

Explore the words cloud of the TiDrugArchitectures project. It provides you a very rough idea of what is the project "TiDrugArchitectures" about.

cell    therapeutic    drugs    molecules    linked    hydrophilicity    vitro    safe    maintaining    direct    cellular    biocompatible    mechanism    frameworks    options    polymeric    chemical    tiiv    phenolato    active    derivatives    donors    bioactive    combine    linear    sites    dissociation    possibly    selective    peptides    rigid    group    transport    cells    geometries    entities    anticancer    hormone    enhanced    cages    bulk    compound    constructed    superior    synergistic    conjugates    optimal    binding    species    dendritic    selectivity    assemblies    sensitive    tshuva    directions    biological    complexes    biochemistry    ph    redox    customized    incorporating    action    small    combination    markedly    stability    water    penetration    dependent    custom    mystery    moieties    unraveling    accessibility    release    steroid    selectively    pt    tumor    medicinal    yield    analyzing    desired    shown    types    interaction    multiple    penetrating    vivo    3d    unlimited    steric    bio    centers    agents    flexible    stable    metal    permeability    cancer    conjugate    bonds    designed   

Project "TiDrugArchitectures" data sheet

The following table provides information about the project.

Coordinator
THE HEBREW UNIVERSITY OF JERUSALEM 

Organization address
address: EDMOND J SAFRA CAMPUS GIVAT RAM
city: JERUSALEM
postcode: 91904
website: www.huji.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙000˙000 €
 EC max contribution 2˙000˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-CoG
 Funding Scheme ERC-COG
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) coordinator 2˙000˙000.00

Map

 Project objective

This proposal aims to develop custom designed anticancer therapeutic frameworks that are effective, stable, safe, and tumor targeted, based on the biocompatible TiIV metal. The Tshuva group has established that water stable phenolato TiIV complexes are especially effective as anticancer agents both in vitro and in vivo, with markedly reduced side effects. Optimal derivatives will be developed to combine activity, stability, and biological accessibility, by maintaining small steric bulk while incorporating strong binding donors and hydrophilicity. The mechanism of action will be investigated by chemical and biological methods, including analyzing bio-distribution, cellular pathways and targets, and interaction with bio-molecules. Specifically, the active metal centers will be linked to bioactive moieties through redox-sensitive S–S bonds to enable tumor targeting. Cell penetrating peptides will facilitate cellular penetration for redox-dependent release of the active species selectively in cancer cells; steroid moieties will direct selectivity to hormone-dependent cancer cell types. Since the combination of TiIV- with Pt-based drugs has shown synergistic effects, multi-active entities will include two or more metal centers, possibly also linked to a transport unit. In addition to linear conjugates, polymeric and dendritic assemblies, exploiting the enhanced permeability of cancer cells, will be constructed with theoretically unlimited options for targeted delivery of multiple active sites. Most importantly, flexible well-defined redox-sensitive cages, as well as rigid pH sensitive complex cages, constructed with customized 3D geometries, will enable specific targeting of any active compound or conjugate and selective dissociation only where desired. This study should yield superior anticancer drugs, while unraveling the mystery of their complex biochemistry, and will contribute to the development of novel chemical and medicinal research directions and applications.

 Publications

year authors and title journal last update
List of publications.
2018 Maya Miller, Edit Y. Tshuva
Racemic vs. enantiopure inert Ti( iv ) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines
published pages: 39731-39734, ISSN: 2046-2069, DOI: 10.1039/c8ra08925f
RSC Advances 8/69 2019-08-29
2018 Avia Tzubery, Naomi Melamed-Book, Edit Y. Tshuva
Fluorescent antitumor titanium( iv ) salen complexes for cell imaging
published pages: 3669-3673, ISSN: 1477-9226, DOI: 10.1039/c7dt04828a
Dalton Transactions 47/11 2019-05-10

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIDRUGARCHITECTURES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIDRUGARCHITECTURES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CohoSing (2019)

Cohomology and Singularities

Read More  

CARBYNE (2020)

New carbon reactivity rules for molecular editing

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More